0001181431-11-029016.txt : 20110512 0001181431-11-029016.hdr.sgml : 20110512 20110512103744 ACCESSION NUMBER: 0001181431-11-029016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110511 FILED AS OF DATE: 20110512 DATE AS OF CHANGE: 20110512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BONDURANT STUART CENTRAL INDEX KEY: 0001181152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34641 FILM NUMBER: 11834255 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Furiex Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001484478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271197863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3900 PARAMOUNT PARKWAY STREET 2: SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-456-7800 MAIL ADDRESS: STREET 1: 3900 PARAMOUNT PARKWAY STREET 2: SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: PPD Therapeutics, Inc. DATE OF NAME CHANGE: 20100218 4 1 rrd311326.xml FORM 4 X0303 4 2011-05-11 0 0001484478 Furiex Pharmaceuticals, Inc. FURX 0001181152 BONDURANT STUART C/O FURIEX PHARMACEUTICALS, INC. 3900 PARAMOUNT PARKWAY, SUITE 150 MORRISVILLE NC 27560 1 0 0 0 Common Stock 2011-05-11 4 P 0 3300 15.2496 A 3896 D Stock Options (to buy) 9.11 2020-06-17 Common Stock 17570 17570 D The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.24 to $15.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. The options were awarded on 6/17/2010 and vest and become exercisable in full on the earlier of the first anniversary of the date of grant or immediately prior to the next election of directors of the Company, provided that the Optionee is still at that time serving on the Company's Board of Directors. /s/ Stuart Bondurant 2011-05-11